Distinct biologisal activities of recombinant forms of human interleukin-2 in vivo

Cancer Immunology Immunotherapy

Volumn 43, Issue 6, 1997, Pages 331-336

  Lentsch, Alex B ^a,b   Nakagawa, Koji ^a   Yoshidome, Hiroyuki ^a   Gerassimides, Alexandra ^a   Miller, Frederick N ^a   Edwards, Michael J ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cytokines; Hepatotoxicity; Inflammation; Mice

Indexed keywords

CYTOKINE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; RECOMBINANT INTERLEUKIN 2; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; FLOW CYTOMETRY; LIVER INJURY; LIVER TOXICITY; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; ANIMAL; C57BL MOUSE; COMPARATIVE STUDY; DRUG EFFECT; HUMAN;

ANIMALS; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS;

EID: 0030615093     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050341     Document Type: Article

References (36)

1. Morgan DA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193: 1007
2. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823
3. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271: 907
4. Siegel JP, Puri RK (1991) Interleukin-2 toxicity. J Clin Oncol 9: 694
5. Taniguchi T, Matsui H, Fujita T, Takaoka C, Kashima N, Yoshimoto R, Hamuro J (1983) Structure and expression of a cloned cDNA for human interleukin-2. Nature 302: 305
6. Wang A, Lu SD, Mark DF (1984) Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues. Science 224: 1431
7. Edwards MJ, Heniford BT, Klar EA, Doak KW, Miller FN (1992) Pentoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves antitumor efficacy. J Clin Invest 90: 637
8. Gately MK, Anderson TD, Hayes TJ (1988) Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice. J Immunol 141: 189
9. Welbourn R, Goldman G, Kobzik L, Paterson I, Shepro D, Hechtman HB (1991) Interleukin-2 induces early multisystem organ edema mediated by neutrophils. Ann Surg 214: 181
10. Edwards MJ, Miller FN, Sims DE, Abney DL, Schuschke DA, Corey TS (1992) Interleukin 2 acutely induces platelet and neutrophil-endothelial adherence and macromolecular leakage. Cancer Res 52: 3425
11. Anderson PM, Sorenson MA (1994) Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin Pharmacokinet 27: 19
12. Gearing AJ, Thorpe R (1988) The international standard for human interleukin-2. Calibration by international collaborative study. J Immunol Methods 114: 3
13. Doyle MV, Lee MT, Fong S (1985) Comparison of the biological activities of human recombinant interleukin-2(125) and native interleukin-2. J Biol Response Mod 4: 96
14. Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark DF (1984) Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 223: 1412
15. Frasier-Scott K, Hatzakis H, Seong D, Jones DM, Wu KK (1988) Influence of natural and recombinant interleukin-2 on endothelial cell arachidonate metabolism. Induction of de novo synthesis of prostaglandin H synthase. J Clin Invest 82: 1877
16. Anderson JA, Lentsch AB, Hadjiminas DJ, Miller FN, Martin AW, Nakagawa K, Edwards MJ (1996) The role of cytokines, adhesion molecules, and chemokines in interleukin-2-induced lymphocytic infiltration in C57BL/6 mice. J Clin Invest 97: 1952
17. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156
18. Lentsch AB, Edwards MJ, Sims DE, Nakagawa K, Wellhausen SR, Miller FN (1996) Interleukin-10 inhibits interleukin-2-induced tumor necrosis factor production but does not reduce toxicity in C3H/HeN mice. J Leukoc Biol 60: 51
19. Gillis S, Ferm MM, Ou W, Smith KA (1978) T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 120: 2027
20. Suave K, Nachman C, Spence C, Bailon P, Campbell E, Tsien WH, Kondas JA, Hakimi J, Ju G (1991) Localization in human interleukin 2 of the binding site of the a chain (p55) of the interleukin 2 receptor. Proc Natl Acad Sci USA 88: 4636
21. Nakagawa K, Miller FN, Sims DE, Lentsch AB, Miyazaki M, Edwards MJ (1996) Mechanisms of interleukin-2-induced hepatic toxicity. Cancer Res 56: 507
22. Ohkubo C, Bigos D, Jain RK (1991) Interleukin 2 induced leukocyte adhesion to the normal and tumor microvascular endothelium in vivo and its inhibition by dextran sulfate: implications for vascular leak syndrome. Cancer Res 51: 1561
23. Anderson TD, Hayes TJ, Gately MK, Bontempo JM, Stern LL, Truitt GA (1988) Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes. Separation of efficacy and toxicity by selective lymphocyte subset depletion. Lab Invest 59: 598
24. Springer TA (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76: 301
25. Vachula M, Van Epps DE (1992) In vitro models of lymphocyte transendothelial migration. Invasion Metastasis 12: 66
26. Oleksowicz L, Zuckerman D, Mrowiec Z, Puszkin E, Dutcher JP (1994) Effects of interleukin-2 administration on platelet function in cancer patients. Am J Hematol 45: 224
27. Weidmann E, Bergmann L, Stock J, Kirsten R, Mitrou PS (1992) Rapid cytokine release in cancer patients treated with interleukin-2. J Immunother 12: 123
28. Numerof RP, Aronson FR, Mier JW (1988) IL-2 stimulates production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear cells. J Immunol 141: 4250
29. Endo Y, Nakamura M (1992) The effect of lipopolysaccharide interleukin-1 and tumour necrosis factor on the hepatic accumulation of 5-hydroxytryptamine and platelets in the mouse. Br J Pharmacol 105: 613
30. Endo Y, Nakamura M (1993) Active translocation of platelets into sinusoidal and Disse spaces in the liver in response to lipopolysaccharides, interleukin-1 and tumor necrosis factor. Gen Pharmacol 24: 1039
31. Feingold KR, Soued M, Serio MK, Moser AH, Dinarello CA, Grunfeld C (1989) Multiple cytokines stimulate hepatic lipid synthesis in vivo. Endocrinology 125: 267
32. Hicks C, Cooley MA, Penny R (1991) Investigation of interleukin 2 receptors on human endothelial cells. Growth Factors 5: 201
33. Cozzolino F, Torcia M, Lucibello M, Morbidelli L, Ziche M, Platt J, Fabiani S, Brett J, Stern D (1993) Interferon-alpha and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth. J Clin Invest 91: 2504
34. Bucana CD, Trial J, Papp AC, Wu KK (1988) Bovine aorta endothelial cell incubation with interleukin 2: morphological changes correlate with enhanced vascular permeability. Scanning Microsc 2: 1559
35. Damle NK, Doyle LV (1989) IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leak syndrome. J Immunol 142: 2660
36. Ferro TJ, Johnson A, Everitt J, Malik AB (1989) IL-2 induces pulmonary edema and vasoconstriction independent of circulating lymphocytes. J Immunol 142: 1916